Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case–control study.

This document is a supplementary information section of a study conducted by the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The study aimed to investigate the factors associated with super responders (SRs) and super nonresponders (SNRs) to biologic therapies in patients with psoriasis. The study found that female sex, shorter study follow-up, higher Dermatology Life Quality Index (DLQI), high frequency of adalimumab, lower frequency of ustekinumab at registration, and higher number of comorbidities were associated with SNRs compared with SRs. The study also mentioned that genetic factors, socioeconomic status, lifestyle factors, adherence to medication, immunogenicity, microbiome, epigenetics, and serum drug levels may play a role in determining treatment response. [Extracted from the article]